MUC1 and COVID-19: Another finding is that KL-6 was higher in ILDs compared to severe cases of COVID-19, confirming the reliability of KL-6 as a serum assessment of ILDs’ severity and suggesting a promising serum biomarker in the early stages of lung injury in COVID-19.